PE anti-mouse CD274 (B7-H1, PD-L1) Antibody

Pricing & Availability
Clone
10F.9G2 (See other available formats)
Regulatory Status
RUO
Other Names
B7-H1, PD-L1
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
10Fdot9G2_PE_030308
C57/B6 mouse splenocytes were stained with anti-CD274 (clone 10F.9G2) PE (filled histogram) or rat IgG2b, κ PE (open histogram).
  • 10Fdot9G2_PE_030308
    C57/B6 mouse splenocytes were stained with anti-CD274 (clone 10F.9G2) PE (filled histogram) or rat IgG2b, κ PE (open histogram).
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
124307 25 µg 53€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
124308 100 µg 155€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Formulation
Phosphate buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunofluorescence4, blocking6,7,8,9, and immunohistochemistry of acetone-fixed frozen sections4, 11. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 124303). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 124318) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References
  1. Maier H, et al. 2007. J. Immunol. 178:2714.
  2. Meng Q, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:4444. PubMed
  3. Scarlett UK, et al. 2012. J Exp Med. 209:495. PubMed
  4. Grabie N, et al. 2007. Circulation 116:2062. (IF, IHC)
  5. Paterson AM, et al. 2011. J. Immunol. 187:1097.
  6. Channappanavar R, et al. 2012. PLoS One 7:e39757. (Block)
  7. Schreiber HA, et al. 2010. PLoS One 5:e11453. (Block) PubMed
  8. Muthumani K, et al. 2011. J. Immunol. 187:2932. (Block) PubMed
  9. Cripps JG, et al. 2010. Hepatology 52:1350. (Block) PubMed
  10. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  11. Riella LV, et al. 2011. Am. J. Transplant 11:832-40. (IHC)
  12. Lei GS, et al. 2015. Infect Immun. 83:572. PubMed
Product Citations
  1. Sandu I, et al. 2020. Nat Commun. 11:4454. PubMed
  2. Xiong W, et al. 2022. Nat Commun. 13:1700. PubMed
  3. Yoon HJ, et al. 2022. Exp Mol Med. Online ahead of print. PubMed
  4. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  5. Mulder R, et al. 2017. Front Immunol. 1.464583333. PubMed
  6. Fitzgerald B, et al. 2021. Cell Rep Methods. 1:. PubMed
  7. Iwasaki Y, et al. 2016. PLoS One. 11: 0158282. PubMed
  8. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  9. Shi J, et al. 2018. Immunity. 49:264. PubMed
  10. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
  11. Mardomi A, et al. 2021. J Cell Physiol. 236:6328. PubMed
  12. Yang M, et al. 2020. Appl Environ Microbiol. 86:00:00. PubMed
  13. Lu SX, et al. 2021. Cell. . PubMed
  14. Nagai Y, et al. 2019. Front Immunol. 10:174. PubMed
  15. Zhang C, et al. 2021. Clin Transl Immunology. 10:e1310. PubMed
  16. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  17. Dichtl S, et al. 2021. Sci Adv. 7: . PubMed
  18. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  19. Vackova J, et al. 2020. Int J Mol Sci. 21:00. PubMed
  20. Jansen MAA, et al. 2019. Front Immunol. 1.852777778. PubMed
  21. Shen Y, et al. 2022. CNS Neurosci Ther. 28:46. PubMed
  22. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  23. Zhang S, et al. 2019. Mol Med Rep. 19:5377. PubMed
  24. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  25. Pauken KE, et al. 2020. Cell Reports. 31(13):107827. PubMed
  26. Guo Q, et al. 2022. Nat Commun. 13:3837. PubMed
  27. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  28. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  29. Zhu XG, et al. 2020. Cell Metabolism. 33(1):211-221.e6. PubMed
  30. Wu Y, et al. 2021. Nat Commun. 12:2346. PubMed
  31. Ramos RN, et al. 2022. Clin Transl Immunology. 11:e1392. PubMed
  32. Lasso P, et al. 2020. Front Immunol. 584959:11. PubMed
  33. Takano T, et al. 2020. Front Immunol. 11:1555. PubMed
  34. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  35. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  36. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  37. Sheng W et al. 2018. Cell. 174(3):549-563 . PubMed
  38. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  39. Webb ER, et al. 2022. iScience. 25:104995. PubMed
  40. Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed
  41. Moon S, et al. 2021. J Exp Med. 218:. PubMed
  42. Shen JZ, et al. 2020. Cell. 184(2):352-369.e23. PubMed
  43. van Oostrum M, et al. 2019. Nat Commun. 4.398611111. PubMed
  44. Lozano-Rodríguez R, et al. 2022. Cell Rep. 38:110235. PubMed
  45. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  46. Lastwika K, et al. 2016. Cancer Res . 76: 227 - 238. PubMed
  47. Ou YC, et al. 2020. ACS Nano. 1.035416667. PubMed
  48. Campesato LF, et al. 2020. Nat Commun. 3.24375. PubMed
  49. Kriegsman BA, et al. 2019. J Immunol. 203:1999. PubMed
  50. Dimitrov V, et al. 2017. J Biol Chem. 292:20657. PubMed
  51. Zhao Y et al. 2018. Cell reports. 24(2):379-390 . PubMed
  52. Zhang X, et al. 2021. Nat Commun. 12:4536. PubMed
  53. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
  54. Apte S, et al. 2011. Int J Parasitol. 41:1285. PubMed
  55. Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
  56. Zhao Y, et al. 2020. Immunity. 51(6):1059-1073.e9.. PubMed
  57. Piñón-Zárate G, et al. 2022. Molecules. 27:. PubMed
  58. Sugita S, et al. 2013. Invest Ophthalmol Vis Sci . 54:3420. PubMed
  59. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  60. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  61. Dai X, et al. 2021. Molecular Cell. 81(11):2317-2331.e6. PubMed
  62. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  63. Zhou Y, et al. 2022. Front Oncol. 12:825783. PubMed
  64. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  65. Nakagawa Y, et al. 2015. Immunol Lett. 167: 72-86. PubMed
  66. Yamashita M, et al. 2019. Cell Stem Cell. 25:357. PubMed
  67. Akhand SS, et al. 2020. Cancer Immunol Res. 8:1542. PubMed
  68. Strait AA, et al. 2021. Commun Biol. 4:1005. PubMed
  69. Zheng Y, et al. 2022. Transl Res. :. PubMed
  70. Zhang Z, et al. 2022. J Inflamm Res. 15:5595. PubMed
  71. Kim SI, et al. 2020. Molecular Cancer Therapeutics. 20(1):173-182. PubMed
  72. Wang J, et al. 2020. J Hematol Oncol. 0.610416667. PubMed
  73. Haile S, et al. 2011. J Immunol. 186:6822. PubMed
  74. Sethuraman SN, et al. 2020. Theranostics. 10:3397. PubMed
  75. Wang H, et al. 2022. J Cancer. 13:2126. PubMed
  76. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  77. Zuo S, et al. 2021. EBioMedicine. 64:103240. PubMed
  78. Loptez-Albraitero A, et al. 2017. OncoImmunology. 10.1080/2162402X.2016.1267891. PubMed
  79. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
RRID
AB_2073557 (BioLegend Cat. No. 124307)
AB_2073556 (BioLegend Cat. No. 124308)

Antigen Details

Structure
40 kD type I transmembrane protein member of B7 family within the immunoglobulin receptor superfamily
Distribution

T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes

Ligand/Receptor
PD-1 (PDCD1)
Cell Type
B cells, Dendritic cells, Endothelial cells, Monocytes, NK cells, T cells
Biology Area
Cancer Biomarkers, Costimulatory Molecules, Immunology
Molecular Family
Adhesion Molecules, CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Sharpe A, et al. 2007. Nat. Immunol. 8:239.
2. Dong H, et al. 1999. Nat. Med. 5:1365.
3. Freeman G, et al. 2000. J. Exp. Med. 192:1027.

Gene ID
60533 View all products for this Gene ID
UniProt
View information about CD274 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 2    Revision Date: 12/22/2014

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

  • Purified anti-mouse CD274 (B7-H1, PD-L1)

  • Biotin anti-mouse CD274 (B7-H1, PD-L1)

  • PE anti-mouse CD274 (B7-H1, PD-L1)

  • Brilliant Violet 421™ anti-mouse CD274 (B7-H1, PD-L1)

  • APC anti-mouse CD274 (B7-H1, PD-L1)

  • PE/Cyanine7 anti-mouse CD274 (B7-H1, PD-L1)

  • Ultra-LEAF™ Purified anti-mouse CD274 (B7-H1, PD-L1)

  • Brilliant Violet 711™ anti-mouse CD274 (B7-H1, PD-L1)

  • Brilliant Violet 605™ anti-mouse CD274 (B7-H1, PD-L1)

  • PE/Dazzle™ 594 anti-mouse CD274 (B7-H1, PD-L1)

  • GoInVivo™ Purified anti-mouse CD274 (B7-H1, PD-L1)

  • Brilliant Violet 785™ anti-mouse CD274 (B7-H1, PD-L1)

  • PerCP/Cyanine5.5 anti-mouse CD274 (B7-H1, PD-L1)

  • Brilliant Violet 650™ anti-mouse CD274 (B7-H1, PD-L1)

  • PE/Cyanine5 anti-mouse CD274 (B7-H1, PD-L1)

  • PE/Fire™ 640 anti-mouse CD274 (B7-H1, PD-L1)

  • Spark Red™ 718 anti-mouse CD274 (B7-H1, PD-L1)

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account